Sort
4,870 grants matching “glp 1”
ANALOGS OF HPMPA FOR TREATMENT OF SMALLPOX
$1,391,660Veterans Medical Research Fdn/San Diego · R01 · FY2005 · AI
Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility
$1,389,051Rima Janusziewicz · Anelleo, Inc. · R44 · FY2024 · HD
Theraupeutic Candidates for Huntington's Disease: From Lead to IND
$1,383,123Aleksey Gregory Kazantsev · Massachusetts General Hospital · U01 · FY2010 · NS
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$1,382,636D. Martin Watterson · Northwestern University At Chicago · U01 · FY2016 · AG
Long-acting ghrelin for the treatment of cancer cachexia
$1,377,076Tarik Soliman · Extend Biosciences, Inc. · R44 · FY2018 · CA
Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer
$1,375,908Beatrice Langton-Webster · Cancer Targeted Technology, Llc · R44 · FY2019 · CA
Synthetic microparticle malaria vaccine
$1,372,308Thomas J Powell · Artificial Cell Technologies, Inc. · R44 · FY2014 · AI
Gene Therapy for Brain Tumors
$1,371,426Fred H Hochberg · Massachusetts General Hospital · P01 · FY2008 · CA
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
$1,370,663D. Martin Watterson · Northwestern University At Chicago · U01 · FY2024 · AG
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$1,370,501Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study
$1,367,955James G. Moe · Oligomerix, Inc · R44 · FY2023 · AG
Protective Mechanisms In Cerebral Ischemia
$1,365,943John Hallenbeck · National Institute Of Neurological Disorders And Stroke · ZIA · FY2011 · NS
Novel Cannabinoid Receptor Modulators
$1,365,662Malliga Iyer · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2025 · AA
Reducing Plasma Cholesterol and Atherosclerosis Using miR-30c Analog C2
$1,364,153M Mahmood Hussain · New York University D/B/A Nyu Long Island School Of Medicine · R01 · FY2025 · HL
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,362,765David S Perlin · Hackensack University Medical Center · R01 · FY2019 · AI
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer
$1,362,268Jim Rotolo · Sapience Therapeutics, Inc. · R44 · FY2023 · CA
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
$1,360,328David M Gamm · University Of Wisconsin-Madison · U19 · FY2023 · NS
IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients
$1,358,179Kevin Strange · Revidia Therapeutics, Inc · R44 · FY2024 · HL
Gene Therapy for Brain Tumors
$1,357,853Fred H Hochberg · Massachusetts General Hospital · P01 · FY2007 · CA
Preclinical drug development in pancreatic cancer
$1,356,844Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Theraupeutic Candidates for Huntington's Disease: From Lead to IND
$1,354,422Aleksey Gregory Kazantsev · Massachusetts General Hospital · U01 · FY2014 · NS
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders
$1,348,795Michael Jackson · Sanford Burnham Prebys Medical Discovery Institute · UH3 · FY2024 · DA
Novel Adjunctive Therapies for NeuroAIDS
$1,344,864Harris A Gelbard · University Of Rochester · P01 · FY2014 · MH
Novel Adjunctive Therapies for NeuroAIDS
$1,344,864Harris A Gelbard · University Of Rochester · P01 · FY2012 · MH
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
$1,342,268William A. Beltran · University Of Pennsylvania · R24 · FY2014 · EY